Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
PFE News
Pfizer (PFE) could use its connections within President Donald Trump’s administration to try to best Novo Nordisk’s (NVO) rival bid to acquire U.S. obesity biot...
Danish drug giant Novo Nordisk (NVO) has been accused by rival Pfizer (PFE) of being “reckless” after it tried to hijack the U.S. firm’s agreed deal with obesit...
Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo...
Analyst ratings
58%
of 24 ratingsMore PFE News
Novo Nordisk (NVO) kicked off a new battle with Pfizer (PFE) on Thursday by making an unsolicited $6.5 billion bid for obesity-focused takeover target, Metsera...
Novo Nordisk (NVO) on Thursday launched an unsolicited bid valued at up to $9B for obesity-drug developer Metsera (MTSR), hoping to top the deal Pfizer (PFE) re...
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO). Metsera said the proposal constitutes a...
Danish drugmaker Novo Nordisk A/S offered to acquire obesity startup Metsera Inc. for at least $6.5 billion, seeking to trump an agreed deal with Pfizer Inc. so...
Key Points Verizon has hiked its dividends for 19 consecutive years, and today boasts a yield of about 7%. Pfizer has been paying dividends for 87 straight ye...
On CNBC's “Mad Money Lightning Round,” on Tuesday, Jim Cramer said Sempra (NYSE:SRE) is a buy. Supporting his view, Wells Fargo analyst Shahriar Pourreza initi...
If you were holding Pfizer stock a year ago, you probably felt the sting of watching the share price drift lower. But does that mean it’s time to give up, or co...
